Adaptimmune Announces Changes to Board and Executive Leadership Team
Adaptimmune (OTC Pink: ADAPY) announced Board and executive changes effective November 14, 2025, including the appointment of Chris Hill as CEO while he continues as CFO and Director, and Lawrence Alleva as Chairman.
The company confirmed the voluntary delisting of ADSs from Nasdaq on October 28, 2025 and initiated deregistration under Section 12(b) with Form 25 and Form 15 filings; deregistration is expected around January 26, 2026. Adaptimmune said a transaction with US WorldMeds closed on July 31, 2025 to keep TECELRA available while the company focuses on maximizing value from remaining programs including PRAME and CD70.
Adaptimmune (OTC Pink: ADAPY) ha annunciato cambiamenti nel consiglio di amministrazione e dirigenza con effetto dal 14 novembre 2025, tra cui la nomina di Chris Hill come CEO mentre continua anche nei ruoli di CFO e Direttore, e Lawrence Alleva come Presidente.
L'azienda ha confermato la delisting volontario delle ADS dalla Nasdaq il 28 ottobre 2025 e ha avviato la deregistrazione ai sensi della Sezione 12(b) con le richieste Form 25 e Form 15; si prevede la deregistrazione intorno al 26 gennaio 2026. Adaptimmune ha riferito che una transazione con US WorldMeds si è chiusa il 31 luglio 2025 per mantenere TECELRA disponibile mentre l'azienda si concentra sulla massimizzazione del valore dei programmi rimanenti, tra cui PRAME e CD70.
Adaptimmune (OTC Pink: ADAPY) anunció cambios en la Junta y en la gerencia con efecto a partir del 14 de noviembre de 2025, incluyendo el nombramiento de Chris Hill como CEO mientras continúa como CFO y Director, y Lawrence Alleva como Presidente.
La compañía confirmó la salida voluntaria de las ADS de Nasdaq el 28 de octubre de 2025 y dio inicio a la deregistración conforme a la Sección 12(b) con los formularios Form 25 y Form 15; se espera la deregistración alrededor del 26 de enero de 2026. Adaptimmune indicó que una transacción con US WorldMeds se cerró el 31 de julio de 2025 para mantener TECELRA disponible mientras la empresa se enfoca en maximizar el valor de los programas restantes, incluidos PRAME y CD70.
Adaptimmune (OTC Pink: ADAPY)는 2025년 11월 14일부로 이사회 및 경영진에 대한 변화를 발표했으며, Chris Hill를 CEO로 임명하는 한편 그가 CFO 및 이사로 계속 재직하고, Lawrence Alleva를 회장으로 임명합니다.
회사는 2025년 10월 28일 Nasdaq에서 ADS를 자발적으로 상장폐지했고, Form 25 및 Form 15 신청과 함께 Section 12(b)에 따른 등록 해제 절차를 시작했습니다; 등록 해제는 2026년 1월 26일경에 예상됩니다. Adaptimmune은 US WorldMeds와의 거래가 2025년 7월 31일에 종료되어 TECELRA를 유지하고, 남은 프로그램의 가치 극대화에 집중하는 동안 PRAME과 CD70를 포함한 프로그램에 집중할 것이라고 밝혔습니다.
Adaptimmune (OTC Pink: ADAPY) a annoncé des changements au sein du conseil d'administration et de la direction qui prendront effet le 14 novembre 2025, notamment la nomination de Chris Hill au poste de PDG tout en restant CFO et Directeur, et Lawrence Alleva comme Président.
La société a confirmé la désinscription volontaire des ADS de Nasdaq le 28 octobre 2025 et a engagé une désenregistrement en vertu de la Section 12(b) avec les formulaires Form 25 et Form 15; la désenregistrement est prévu autour du 26 janvier 2026. Adaptimmune a indiqué qu'une transaction avec US WorldMeds a été clôturée le 31 juillet 2025 afin de maintenir TECELRA disponible pendant que l'entreprise se concentre sur la maximisation de la valeur des programmes restants, dont PRAME et CD70.
Adaptimmune (OTC Pink: ADAPY) kündigte ab dem 14. November 2025 Änderungen im Vorstand und im Führungsteam an, darunter die Ernennung von Chris Hill zum CEO, während er weiterhin als CFO und Direktor tätig ist, sowie Lawrence Alleva als Vorsitzender.
Das Unternehmen bestätigte den freiwilligen Delisting der ADS von Nasdaq am 28. Oktober 2025 und leitete die Entregistrierung gemäß Section 12(b) mit Form 25 und Form 15 ein; eine Entregistrierung wird voraussichtlich um den 26. Januar 2026 erfolgen. Adaptimmune erklärte, dass eine Transaktion mit US WorldMeds am 31. Juli 2025 abgeschlossen wurde, um TECELRA verfügbar zu halten, während sich das Unternehmen darauf konzentriert, den Wert der verbleibenden Programme wie PRAME und CD70 zu maximieren.
Adaptimmune (OTC Pink: ADAPY) أعلنت عن تغييرات في المجلس التنفيذي والإدارة سارية اعتباراً من 14 نوفمبر 2025، بما في ذلك تعيين Chris Hill كرئيس تنفيذي بينما يظل مديراً مالياً ورئيساً للمديرين، وLawrence Alleva رئيساً للمجلس.
أكّدت الشركة الإلغاء الطوعي لإدراج ADS لدى Nasdaq في 28 أكتوبر 2025 وبدء إيقاف التسجيل وفق القسم 12(b مع تقديم النموذجين Form 25 وForm 15؛ من المتوقع أن يتم إلغاء التسجيل حوالي 26 يناير 2026. قالت Adaptimmune إن صفقة مع US WorldMeds أُغلِقت في 31 يوليو 2025 للحفاظ على TECELRA متاحاً بينما تركز الشركة على تعظيم قيمة البرامج المتبقية بما فيها PRAME و CD70.
- Transaction with US WorldMeds closed on July 31, 2025
- Deregistration expected to reduce public-company costs
- Company retains focus on PRAME and CD70 programs
- Multiple directors resigned reducing Board to three members
- CEO also serving concurrently as CFO
- Deregistration suspends Exchange Act filing obligations upon Form 15
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025.
Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company, succeeding Adrian Rawcliffe who has left in connection with the Company's restructuring. Mr. Hill is continuing to serve as CFO. William (Bill) Bertrand, formerly Chief Operating Officer, has also left the Company in connection with the restructuring.
Lawrence Alleva, a current Board member, has been appointed as Chairman of the Company succeeding David Mott who has served as a director since 2014 and as Chairman since 2017. Garry Menzel will also continue to serve on the Board. In addition to Mr. Mott, the following Board members have resigned: Andrew Allen, Ali Behbahani, John Furey, Priti Hegde and Kristen Hege.
Following the changes, the Board comprises Lawrence Alleva (Chairman), Garry Menzel and Chris Hill (also CEO and CFO).
The changes follow on from the voluntary delisting of the Company's American Depositary Shares ("ADSs") from Nasdaq on October 28, 2025. The Company's ADSs are quoted on the OTC Pink Limited Market under the symbol ADAPY.
Chris Hill, Adaptimmune's new Chief Executive Officer: "I am pleased to have been appointed to succeed Adrian who has served with Adaptimmune since 2015 as CFO and then CEO. I want to acknowledge the work of Adrian, Bill and my fellow Board members and thank them for their dedicated service over many years. The transaction with USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, "US WorldMeds") meant that TECELRA could continue to be made available to patients, and since closing on July 31, 2025, work has been ongoing to ensure a smooth transition of activities associated with TECELRA, lete-cel and uza-cel. We will continue to support US WorldMeds as we work together with a goal to achieve approval for lete-cel in the hope that it will benefit patients in the future. In parallel, we are maintaining a focus on efforts to maximize value from our remaining assets, including programs targeting PRAME and CD70. The delisting from Nasdaq and deregistration should reduce our costs as a public company and further support our goal to maximize value going forward."
The Company has also initiated a process for deregistration of the ADSs under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") which included the filing of a Form 25 with the Securities and Exchange Commission ("SEC") on October 28, 2025 and of a Form 15 on November 13, 2025, upon which the Company's filing obligations under the Exchange Act were immediately suspended, including the obligations to file all periodic reports. The deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is currently expected to become effective on or around January 26, 2026.
Chris Hill has served as Adaptimmune's Chief Financial Officer since September 10, 2025 leading the Company's financial operations and strategy. He has over 10 years' experience of serving in chief financial officer and chief operating officer roles in public and private life science companies.
From September 2021 through September 9, 2025, Mr. Hill served as Chief Financial Officer and Chief Operating Officer of Istesso Limited, a private drug development company with pre-clinical to phase IIb assets developing new therapies in auto-immune and fibrotic diseases. Previously, Mr. Hill served as part-time Chief Financial Officer of Ixaka Limited, a private cell therapy company, from April 2020 through September 2021 and as Finance Director of OxSonics Therapeutics Limited, a private clinical stage therapeutics company developing improved drug delivery solutions to solid tumour cancers, from March 2019 through September 2021.
Mr. Hill served as Chief Financial Officer and a member of the Board of Directors of Oxford Pharmascience Group Plc, formerly a publicly listed drug development company on AIM focused on gastro-safe NSAIDs, from October 2013 through January 2018. Mr. Hill had responsibility for the financial, legal and HR functions within the group and for AIM and other regulatory reporting. During his tenure, the company underwent a demerger, and its operations were spun out into Abaco Capital (AIM: ABAA) and private company, Oxford Pharmascience Limited. His other prior roles include serving as Group Financial Controller at Ora Capital Partners Limited, previously an AIM-listed investment vehicle, from July 2010 through October 2013, and as Audit Senior at international audit, professional services and consulting firm, Grant Thornton UK LLP, from June 2005 to June 2010. He currently serves as a director of private companies, Connexin Therapeutics Group Limited and CJH Financial Limited.
Mr. Hill is a chartered accountant and holds a B.A. degree in Economics and Public Policy from Leeds Metropolitan University.
About Adaptimmune
We are a biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. In August 2024, the U.S. Food and Drug Administration ("FDA") approved our first biologics license application ("BLA") for TECELRA® (afamitresgene autoleucel) ("TECELRA"), which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S. In July 2025, TECELRA was acquired by US WorldMeds alongside letetresgene autoleucel ("lete-cel"), for people with synovial sarcoma and myxoid liposarcoma, in relation to which a commercial launch was planned for 2026. A third clinical candidate, uza-cel, and the collaboration with Galapagos related to that cell therapy was also assigned to US WorldMeds as part of the transaction. We are working to ensure a smooth transition of TECELRA, lete-cel and uza-cel to US WorldMeds. We have also developed certain pre-clinical assets including our PRAME directed T-cell therapy and our CD-70 directed TRuC therapy. We are looking for strategic options in relation to these assets.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Exchange Act. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: risks associated with the Company's voluntary delisting from Nasdaq and the effectiveness thereof; the Company's plans and timing with respect to the delisting and deregistration of its ADSs; uncertainties regarding eligibility for and timing of quotation on an OTC market; and the trading of the Company's ADSs following the voluntary delisting of the ADSs from Nasdaq. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations and Media Relations
Chris Hill, Chief Executive Officer
ir@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274566
FAQ
Who is the new CEO of Adaptimmune (ADAPY) and when did the appointment take effect?
Why did Adaptimmune (ADAPY) delist from Nasdaq and when did it happen?
What filings did Adaptimmune (ADAPY) make to deregister its ADSs and when will deregistration be effective?
How does the US WorldMeds transaction affect Adaptimmune (ADAPY) products?
What is the current composition of Adaptimmune's (ADAPY) Board after the changes?
What programs is Adaptimmune (ADAPY) prioritizing after the restructuring?
